Unknown

Dataset Information

0

Heterogeneity in Comparisons of Discontinuation of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis - A Meta-Analysis.


ABSTRACT:

Objective

We did a systematic review of studies comparing discontinuation of tumor necrosis factor alpha (TNF) antagonists in rheumatoid arthritis (RA) patients, pooled hazard ratios and assessed clinical and methodological heterogeneity.

Methods

We searched MEDLINE and EMBASE until June 2015 for pairwise hazard ratios for discontinuing infliximab, etanercept, and adalimumab from cohorts of RA patients. Hazard ratios were pooled using inverse variance weighting and random effects estimates of the combined hazard ratio were obtained. Clinical and methodological heterogeneity was assessed using the between-subgroup I-square statistics and meta-regression.

Results

Twenty-four unique studies were eligible and large heterogeneity (I-square statistics > 50%) was observed in all comparisons. Type of data, location, and order of treatment (first or second line) modified the magnitude and direction of discontinuation comparing infliximab with either adalimumab or etanercept; however, some heterogeneity remained. No effect modifier was identified when adalimumab and etanercept were compared.

Conclusion

Heterogeneity in studies comparing discontinuation of TNF antagonists in RA is partially explained by type of data, location, and order of treatment. Pooling hazard ratios for discontinuing TNF antagonists is inappropriate because largely unexplained heterogeneity was demonstrated when random effect estimates were calculated.

SUBMITTER: Fisher A 

PROVIDER: S-EPMC5145210 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature

altmetric image

Publications

Heterogeneity in Comparisons of Discontinuation of Tumor Necrosis Factor Antagonists in Rheumatoid Arthritis - A Meta-Analysis.

Fisher Anat A   Bassett Ken K   Goel Gautam G   Stanely Dana D   Brookhart M Alan MA   Freeman Hugh R HR   Wright James M JM   Dormuth Colin R CR  

PloS one 20161208 12


<h4>Objective</h4>We did a systematic review of studies comparing discontinuation of tumor necrosis factor alpha (TNF) antagonists in rheumatoid arthritis (RA) patients, pooled hazard ratios and assessed clinical and methodological heterogeneity.<h4>Methods</h4>We searched MEDLINE and EMBASE until June 2015 for pairwise hazard ratios for discontinuing infliximab, etanercept, and adalimumab from cohorts of RA patients. Hazard ratios were pooled using inverse variance weighting and random effects  ...[more]

Similar Datasets

| S-EPMC4482317 | biostudies-literature
| S-EPMC4883258 | biostudies-other
| S-EPMC6527918 | biostudies-literature
| S-EPMC6437938 | biostudies-literature
| S-EPMC5327780 | biostudies-literature
| S-EPMC6117139 | biostudies-literature
| S-EPMC2745801 | biostudies-literature
| S-EPMC4900733 | biostudies-literature
| S-EPMC7050382 | biostudies-literature
| S-EPMC5510804 | biostudies-literature